Dodd Erin, Hook Kristen
Medical School, University of Minnesota, Minneapolis, Minnesota.
Department of Dermatology, University of Minnesota, Minneapolis, Minnesota.
Pediatr Dermatol. 2016 May;33(3):e184-e185. doi: 10.1111/pde.12829. Epub 2016 Apr 4.
Although topical steroids are considered first-line treatment for cutaneous Langerhans cell histiocytosis (LCH), the appropriate therapy for refractory cases remains controversial. We report a 16-month-old girl with isolated cutaneous LCH refractory to treatment with topical corticosteroids and topical tacrolimus. Treatment was initiated with 5% topical imiquimod cream and the rash completely resolved after 5 months of therapy. There was no disease recurrence after more than 2 years of follow-up. We present this case to highlight imiquimod as a novel therapeutic agent for the management of isolated cutaneous LCH in children.
